Standardised follow-up

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

The NHS Modernisation Agency: Direction of Travel NICE Annual Conference 5 December 2001.
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
A Case Study GP Masterclass Catherine Dale, RN, BSc Cancer Care
Advanced Stage Prostate Cancer Management Michael E. Karellas Assistant Professor of Urologic Oncology May 15, 2010.
Non Acute Scrotal Swelling
British Association of Urological Surgeons Metastatic Prostate Cancer Guidelines.
CCG/QEH Urology Agreements An update for General Practitioners -Edgar Paez-Consultant Urologist -Freeman Hospital –Newcastle upon Tyne and Queen Elizabeth.
PSA & Prostate Cancer Dan Burke Consultant Urological Surgeon
NHS Improvement National Conference Cancer Survivorship – Living with and Beyond Cancer “ACHIEVING EQUITABLE and CONTEMPORARY SERVICES for all Cancer SURVIVORS”
Survivorship Update January 2015 The Royal Wolverhampton NHS Trust James Owen Senior Cancer Services Manager.
In the name of God Isfahan medical school Shahnaz Aram MD.
Prostate Cancer Case Presentation Shireen Siddiqui.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
JCUH NICE MSCC Guidelines Compliance audit Ruth Mhlanga Senior Specialist Physiotherapist Oncology and Haematology.
Prostate cancer Tim Bracey Histopathology. Prostate cancer What are we going to talk about? Anatomy of prostate Anatomy of prostate Very basic histology!
PSA Shared Care Jim Wood. Background A significant number of men with prostate cancer (CaP) are receiving regular hospital follow up (out- patient visits),
Go with the flow: the changing pathways in Urology CATS Urology Clinical Assessment & Treatment Service UROLOGY CATS.
Mark Lynch Clinical Lead Urology, Croydon University Hospital Consultant, St George’s Hospital
EUROPA UOMO European Prostate Passport Recommendations from Berlin
Acute Oncology Dr Nicola Storey.
LOWER URINARY TRACT SYMPTOM MANAGEMENT CLINIC Julia Taylor Nurse Consultant Salford Royal Hospital NHS Foundation Trust.
The Anticoagulation Service at Salisbury District Hospital Nic McQuaid And Rachel Woodford Anticoagulation Nurse Practitioners.
DISCHARGE DEVELOPMENTS ACROSS NORTH GLASGOW OUTPATIENT AND HOME PARENTERAL ANTIBIOTIC THERAPY (OHPAT) SERVICE Lindsay Semple Project Manager/Nurse Specialist.
Melanoma: assessment and management NICE guideline NG14 Full guideline July 2015.
Summary The National Clinical Pathway represents a pathway that is achievable now, requiring no extra resources but reliant on appropriate logistics. The.
Life after Prostate Cancer and its treatment Mr Sanjeev Pathak Consultant Urological Surgeon and Cancer Lead Doncaster and Bassetlaw NHS Trust 12 th March.
True NTH Miranda Benney Macmillan Uro-oncology CNS Beverley Palmer Prostate Cancer Support Worker.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Developing the GP Cancer Lead Community Dr P Sawyer Herts Valleys Macmillan Cancer Lead.
Prostate Cancer David Eedes 11 May Prostate Cancer Definition: Prostate cancer is a disease in which cells in the prostate gland become abnormal.
CANCER CAUSES, REMEDIES & PREVENTION
National Clinical Pathway for suspected and confirmed lung cancer:
OAB / LUTS Urology Pathway for Primary Care within Frimley Health locality Developed with key local stakeholders including Urologists, Gynaecologists,
Avon Local Medical Committee
PSA, PCA-3 and peace of mind in suspected prostate cancer
Carcinoma of Prostate Issam S. Al-Azzawi, MD,FICMS,FEBU By
Breast Cancer Screening/Imaging
Updates in Prostate Cancer Prepared for GP master class – Sept 2016
Bladder Cancer and Prostatic Cancer
Primary Care Stratified Follow-up of Stable Prostate Cancer Patients
Colin Fischbacher Information Services Division (ISD)
Urology Referrals QP Day 5/11/13.
BREAST CANCER ONCOLOGY NAVIGATION SERVICE
Coordination (benign lesions)
Consult timeline & follow-up example from Lily’s Pharmacy
Quality of Referrals Guideline Congruence of referrals to TIAMS clinic
PSO – Paper Switch Off Project
PSA testing.
Pathway for patients with suspected Breast Cancer
Six stage journey When diagnosed with a brain tumour.
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Breast cancer pathway update – Primary care pathways event
Pathway for patients with suspected colorectal cancer
The BAHNO Head & Neck Cancer Surveillance Audit 2018
Antonio Alcaraz, Pierre Teillac  European Urology Supplements 
Initial Office Evaluation
Prostate Cancer Update
Calculate Well’s score for PE (BOX1)
Service Delivery Group – January 2019
Early and locally advanced breast cancer
Pathway for patients with suspected Breast Cancer
Identifying Low-Risk Patients with Pulmonary Embolism Suitable For Outpatient Treatment A VERITY Registry Pilot Study N Scriven, T Farren, S Bacon, T.
28 Day Faster Diagnosis Standard
Squamous cell carcinoma pathway update
Airedale NHS Foundation Trust
Living With & Beyond Cancer (Personalised Care): SWAG Colorectal CAG Update 5th June 2019 Catherine Neck, Macmillan Cancer Rehabilitation/ LWBC Lead On.
Maintaining bone health while on ADT for Prostate Cancer
Advice Guidance & Proceed
Introduction European Urology Supplements
Presentation transcript:

Standardised follow-up Steve Bromage

Urological cancer follow-up Prostate Active surveillance Watchful waiting Post treatment Raised PSA Renal Telephone follow-up Bladder Secondary care (cystoscopic)

Prostate cancer: Active Surveillance Follow-up secondary care Protocols currently being altered due to MRI More stratified follow-up Initially PSA 3 monthly and DRE annually

Watchful waiting Often discharged to primary care PSA 6 monthly- yearly Individual thresholds set Hormone treatment indicated: PSA rising over 50 without significant symptoms Fast doubling time Consider side effects of hormone treatment LHRH agonist vs bicalutamide vs LHRH Antagonist

Ca P : Post treatment NICE Surgery Radiotherapy Check PSA levels …….at least every 6 months for the first 2 years, and then at least once a year after that. [2019 consultation] After at least 6 months’ initial follow-up, consider a non-hospital based follow-up strategy for people with a stable PSA who have had no significant treatment complications, unless they are taking part in a clinical trial that needs formal clinic-based follow-up [2019 consultation] Estimate PSA doubling time if biochemical relapse occurs. Base this on a minimum of 3 measurements over at least a 6-month period. [2008] Surgery Discharge at 2 years PSA yearly and refer back if >0.1 Radiotherapy PSA yearly and refer back if >10

Hormone treated Ca P Often discharged on established hormone treatment PSA yearly basis Re-refer if >10 Symptomatic (worsening LUTS, bony pain) Patient led PSA monitoring Technology EG. MyPSA app Infoflex My Medical Record Somerset Cancer Register

Raised PSA and negative investigations Individualised PSA threshold based MRI PSA PSA density Biopsy Y/N Transperineal vs TRUS Age Risk Factors 2 PSA minimum to generate re-referral

Renal cancer Follow-up Assign risk on histology (low/intermediate/high) Holistic needs assessment Normally CT follow-up for 5-10 years Little requirement for face-face appointments

6 week follow up consultant appointment with histology Surgery for RCC 6 week follow up consultant appointment with histology Nurse appointment for hollistic needs between 6 weeks and 3 months post op Follow-up programme initiated Not suitable for telephone follow up Standard outpatient review Suitable for telephone follow-up Scan organised as per protocol with U and E beforehand Result of scan to consultant or Nurse Abnormal- outpatient appointment No recurrence: nurse telephone follow-up: Next scan organised and U and E 1 month before CT

Questions?